A Phase 1 interventional study of Giredestrant and Surgery in Breast Cancer, sponsored by Genentech, Inc.. Completed at 15 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.
Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 15th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1, and was the 2nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Canada
Ages 18+
Genentech, Inc. · Sites in United States
Ages 18+ · Women only
Hoffmann-La Roche · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18+ · Women only
Fondazione Oncotech · Sites in Italy
Ages 18+ · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, giredestrant is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 302 across the 16 interventional studies. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 118th largest by enrollment of the 170 interventional ones that give a count, is one of 5 that started in 2019, is one of 27 in phase 1, and was the 191st registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing giredestrant in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03332797Genentech, Inc.A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | 2027-07-31 |
| NCT07054190Hoffmann-La RocheA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing giredestrant in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Giredestrant · Procedure: Surgery
Drug: Giredestrant · Procedure: Surgery
Drug: Giredestrant · Procedure: Surgery
Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
Also known as: GDC-9545, RO7197597, RG6171
Breast cancer surgery will take place on Day 15 (+/-2 days).
Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples
The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the proportion of nuclei staining Ki67-positive (Ki67+) in the tumor biopsy sample taken post-treatment (at surgery) relative to that in the pre-treatment sample (at baseline).
Time frame: Baseline and Surgery (Day 15)
Change From Baseline in Tumor Cell Proliferation, as Measured by the Difference in the Percentage of Nuclei Staining Ki67-Positive at Surgery Compared With Baseline in Pre- and Post-Treatment Tumor Biopsy Samples
The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the percentage of nuclei staining Ki67-positive (Ki67+) in the pre- and post-treatment tumor biopsy samples (taken at baseline and surgery, respectively) and the absolute difference in the percentage of Ki67+ nuclei between the two samples (calculated as surgery minus baseline).
Time frame: Baseline and Surgery (Day 15)
Number of Participants With at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)
All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. Investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE was considered to be related to the study drug.
Time frame: From Baseline to Day 43
Percentage of Participants With Abnormal Vital Signs During Treatment
Vital signs, which included diastolic and systolic blood pressure, pulse rate, and body temperature, were measured while the participant was sitting and according to institutional practices. Any of the vital signs that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). A vital sign result had to be reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Baseline, Days 1, 8, and 15
Change From Baseline in Pulse Rate
Pulse rate was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Change From Baseline in Systolic Blood Pressure
Systolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Change From Baseline in Diastolic Blood Pressure
Diastolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Change From Baseline in Body Temperature
Body temperature was measured according to institutional practice. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
Time frame: Baseline, Day 8, Surgery (Day 15), and Post-Surgery (Day 43)
Percentage of Participants With Laboratory Abnormalities in Hematology Tests During Treatment, Among Participants Without the Abnormality at Baseline
Laboratory parameters for hematology will be measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Baseline, Days 1, 8, and 15
Percentage of Participants With Laboratory Abnormalities in Blood Chemistry and Coagulation Tests During Treatment, Among Participants Without the Abnormality at Baseline
Laboratory parameters for blood chemistry and coagulation were measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase
Time frame: Baseline, Days 1, 8, and 15
Percentage of Participants With Abnormal Electrocardiogram Parameters During Treatment
Electrocardiogram (ECG) recordings were performed after the participant had been resting in a supine position for at least 10 minutes. ECG parameters included heart rate, PR and QRS durations, and QT and QTcF intervals. Per the protocol, ECG readings post-treatment were limited to those for whom it was clinically indicated. Any of the ECG parameters that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). An ECG test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
Time frame: Baseline, Days 1, 8, and 15
Plasma Concentration of Giredestrant at Steady State by Dose Level
Plasma samples were obtained on the day of surgery (Day 15), or prior to biopsy on Day 14.
Time frame: Predose on day of surgery (Day 15), or prior to biopsy (Day 14)
| Milestone | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg |
|---|---|---|---|
| Started | 17 | 40 | 18 |
| Received at least one dose of study drug | 17 | 40 | 17 |
| Completed | 17 | 39 | 16 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the proportion of nuclei staining Ki67-positive (Ki67+) in the tumor biopsy sample taken post-treatment (at surgery) relative to that in the pre-treatment sample (at baseline).
| Proportion of Ki67+ nuclei | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Efficacy: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples | 0.20 (0.12 to 0.31) | 0.24 (0.18 to 0.32) | 0.22 (0.13 to 0.37) | 0.22 (0.18 to 0.28) |
The biological response to the study treatment was assessed by measuring changes in cell proliferation (Ki67 expression) using formalin-fixed paraffin-embedded histopathology sections of the tumor biopsy specimens taken at baseline and at day of surgery. Baseline was defined as a sample taken prior to initiation of study drug. The results show the percentage of nuclei staining Ki67-positive (Ki67+) in the pre- and post-treatment tumor biopsy samples (taken at baseline and surgery, respectively) and the absolute difference in the percentage of Ki67+ nuclei between the two samples (calculated as surgery minus baseline).
| Percentage of nuclei Ki67+ | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Efficacy: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 15.70 ± 9.25 | 15.10 ± 11.23 | 15.58 ± 9.95 | 15.35 ± 10.36 |
| Surgery - Value at Visit | 4.22 ± 4.70 | 4.12 ± 4.35 | 4.08 ± 3.80 | 4.13 ± 4.25 |
| Change from BL at Surgery (Surgery minus BL) | -11.49 ± 7.84 | -10.98 ± 8.53 | -11.49 ± 8.23 | -11.21 ± 8.18 |
All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. Investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE was considered to be related to the study drug.
| Participants | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Any Adverse Event (AE) | 12 | 27 | 14 | 53 |
| AE with Fatal Outcome | 0 | 0 | 0 | 0 |
| Serious AE | 1 | 2 | 1 | 4 |
| Related Serious AE | 0 | 0 | 0 | 0 |
| AE Leading to Withdrawal from Study Drug | 0 | 0 | 0 | 0 |
| AE Leading to Interruption of Study Drug | 1 | 0 | 1 | 2 |
| Related AE | 7 | 17 | 8 | 32 |
| Grade 3-4 AE | 1 | 3 | 1 | 5 |
| Related Grade 3-4 AE | 0 | 0 | 0 | 0 |
Vital signs, which included diastolic and systolic blood pressure, pulse rate, and body temperature, were measured while the participant was sitting and according to institutional practices. Any of the vital signs that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). A vital sign result had to be reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Percentage of participants | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Diastolic Blood Pressure - Low | 5.9 | 12.5 | 23.5 | 13.5 |
| Diastolic Blood Pressure - High | 64.7 | 35.0 | 11.8 | 36.5 |
| Systolic Blood Pressure - High | 82.4 | 70.0 | 58.8 | 70.3 |
| Pulse Rate - Low | 11.8 | 27.5 | 64.7 | 32.4 |
| Pulse Rate - High | 0 | 2.5 | 0 | 1.4 |
| Body Temperature - Low | 88.2 | 82.5 | 94.1 | 86.5 |
Pulse rate was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
| beats per minute | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 75.3 ± 9.5 | 72.6 ± 11.1 | 72.1 ± 10.6 | 73.1 ± 10.6 |
| Change from BL at Day 8 | 1.4 ± 8.5 | -1.9 ± 11.3 | -11.1 ± 10.6 | -3.1 ± 11.3 |
| Change from BL at Surgery | 2.4 ± 9.7 | -3.8 ± 10.7 | -13.9 ± 10.8 | -4.5 ± 11.8 |
| Change from BL at Post-Surgery | 2.2 ± 12.0 | 3.5 ± 11.4 | 4.2 ± 11.3 | 3.4 ± 11.4 |
| Change from BL at Post-BL Minimum | -4.2 ± 9.2 | -7.4 ± 9.9 | -14.4 ± 10.7 | -8.3 ± 10.4 |
| Change from BL at Post-BL Maximum | 9.5 ± 7.2 | 6.7 ± 11.1 | 4.8 ± 10.0 | 6.9 ± 10.1 |
Systolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
| millimetres of mercury (mmHg) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 135.4 ± 18.6 | 128.0 ± 14.2 | 129.4 ± 14.7 | 130.0 ± 15.5 |
| Change from BL at Day 8 | -1.1 ± 12.3 | 2.9 ± 14.0 | -7.9 ± 14.3 | -0.3 ± 14.2 |
| Change from BL at Surgery | -2.2 ± 15.7 | 5.7 ± 15.2 | -1.4 ± 17.3 | 2.2 ± 16.0 |
| Change from BL at Post-Surgery | -2.1 ± 14.6 | 1.0 ± 13.2 | -3.2 ± 15.3 | -0.7 ± 13.9 |
| Change from BL at Post-BL Minimum | -9.5 ± 12.0 | -5.5 ± 11.2 | -12.5 ± 14.6 | -8.0 ± 12.4 |
| Change from BL at Post-BL Maximum | 5.9 ± 13.6 | 11.8 ± 13.4 | 3.2 ± 15.2 | 8.5 ± 14.2 |
Diastolic blood pressure was measured while the participant was in a seated position. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
| millimetres of mercury (mmHg) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 78.4 ± 10.3 | 75.2 ± 10.7 | 76.9 ± 10.8 | 76.3 ± 10.6 |
| Change from BL at Day 8 | -3.4 ± 7.3 | -0.5 ± 7.4 | -9.5 ± 10.3 | -3.1 ± 8.7 |
| Change from BL at Surgery | -3.2 ± 7.9 | -2.1 ± 12.5 | -8.3 ± 10.7 | -3.7 ± 11.2 |
| Change from BL at Post-Surgery | 4.1 ± 8.0 | 0.1 ± 10.5 | -4.5 ± 9.8 | 0.0 ± 10.1 |
| Change from BL at Post-BL Minimum | -6.4 ± 6.6 | -6.2 ± 8.7 | -12.2 ± 8.5 | -7.6 ± 8.5 |
| Change from BL at Post-BL Maximum | 5.6 ± 7.0 | 3.8 ± 10.8 | -2.8 ± 9.2 | 2.7 ± 10.1 |
Body temperature was measured according to institutional practice. The baseline value at visit and the change from baseline value at each timepoint are reported. The change from baseline value was calculated by subtracting the post-baseline value from the baseline value. The post-baseline minimum and maximum change from baseline values are, respectively, the smallest and largest value changes obtained after baseline through the last study visit. Baseline was defined as the participant's last value prior to initiation of study drug.
| degrees Celsius (C) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 36.36 ± 0.48 | 36.41 ± 0.38 | 36.25 ± 0.24 | 36.36 ± 0.38 |
| Change from BL at Day 8 | -0.03 ± 0.41 | -0.06 ± 0.51 | -0.09 ± 0.43 | -0.06 ± 0.47 |
| Change from BL at Surgery | 0.14 ± 0.51 | -0.09 ± 0.46 | -0.18 ± 0.43 | -0.05 ± 0.47 |
| Change from BL at Post-Surgery | -0.03 ± 0.56 | -0.05 ± 0.39 | -0.11 ± 0.50 | -0.06 ± 0.45 |
| Change from BL at Post-BL Minimum | -0.20 ± 0.52 | -0.34 ± 0.44 | -0.39 ± 0.42 | -0.32 ± 0.45 |
| Change from BL at Post-BL Maximum | 0.28 ± 0.42 | 0.15 ± 0.44 | 0.12 ± 0.32 | 0.17 ± 0.41 |
Laboratory parameters for hematology will be measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Percentage of participants | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Hematocrit - Low | 0 | 3.2 | 0 | 2.0 |
| Hematocrit - High | 22.2 | 0 | 0 | 4.3 |
| Hemoglobin - Low | 10.0 | 0 | 0 | 2.0 |
| Hemoglobin - High | 0 | 3.1 | 0 | 2.0 |
| Lymphocytes, Absolute Count (Abs) - Low | 0 | 3.1 | 0 | 2.0 |
| Lymphocytes, Abs - High | 0 | 3.2 | 12.5 | 4.1 |
| Neutrophils, Total, Abs - Low | 0 | 3.2 | 0 | 2.0 |
| Erythrocytes - Low | 22.2 | 6.7 | 0 | 8.5 |
| Total Leukocyte Count - Low | 0 | 3.1 | 0 | 2.0 |
Laboratory parameters for blood chemistry and coagulation were measured and compared with a standard reference range. Any of the laboratory test results that were outside of a parameter's normal reference range (in the specified direction - low or high) were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase
| Percentage of participants | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Albumin - Low | 0 | 3.3 | 0 | 2.1 |
| Albumin - High | 0 | 3.3 | 0 | 2.1 |
| Alkaline Phosphatase - High | 0 | 3.4 | 0 | 2.3 |
| SGPT/ALT - High | 0 | 6.7 | 14.3 | 6.5 |
| SGOT/AST - High | 0 | 3.1 | 14.3 | 4.2 |
| Bicarbonate HCO3 - Low | 0 | 3.1 | 0 | 2.0 |
| Bicarbonate HCO3 - High | 16.7 | 9.5 | 40.0 | 15.6 |
| Blood Urea Nitrogen - High | 10.0 | 3.1 | 0 | 4.1 |
| Calcium - High | 0 | 3.1 | 0 | 2.0 |
| Carbon Dioxide - High | 33.3 | 25.0 | 0 | 25.0 |
| Chloride - Low | 10.0 | 3.2 | 12.5 | 6.1 |
| Chloride - High | 0 | 9.4 | 0 | 6.3 |
| Creatinine - High | 0 | 3.1 | 0 | 2.0 |
| Direct Bilirubin - Low | 10.0 | 0 | 0 | 2.4 |
| Direct Bilirubin - High | 11.1 | 3.4 | 0 | 4.3 |
| Glucose, Fasting - High | 0 | 31.3 | 0 | 19.2 |
| Glucose, Fasting Unknown - High | 33.3 | 21.4 | 33.3 | 25.0 |
| Magnesium - High | 0 | 0 | 12.5 | 2.0 |
| Phosphorus - Low | 10.0 | 0 | 0 | 2.0 |
| Phosphorus - High | 0 | 3.2 | 0 | 2.0 |
| Potassium - High | 0 | 3.1 | 0 | 2.0 |
| Sodium - Low | 0 | 3.1 | 0 | 2.0 |
| Bilirubin - High | 0 | 6.7 | 0 | 4.2 |
| Protein, Total - Low | 0 | 3.3 | 0 | 2.2 |
| Protein, Total - High | 0 | 3.2 | 0 | 2.0 |
| Prothrombin Time - High | 0 | 3.0 | 0 | 1.6 |
| International Normalized Ratio - High | 0 | 2.6 | 0 | 1.4 |
| Activated Partial Thromboplastin Time - Low | 13.3 | 16.2 | 11.8 | 14.5 |
Electrocardiogram (ECG) recordings were performed after the participant had been resting in a supine position for at least 10 minutes. ECG parameters included heart rate, PR and QRS durations, and QT and QTcF intervals. Per the protocol, ECG readings post-treatment were limited to those for whom it was clinically indicated. Any of the ECG parameters that were outside of the normal reference range (in the specified direction - low or high) were considered abnormalities. Not every abnormality qualified as an adverse event (AE). An ECG test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.
| Percentage of participants | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety (ECG): Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| PR Duration - Low | 12.5 | 0 | 0 | 5.3 |
| PR Duration - High | 0 | 0 | 25.0 | 5.3 |
Plasma samples were obtained on the day of surgery (Day 15), or prior to biopsy on Day 14.
| nanograms per millilitre (ng/mL) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg |
|---|---|---|---|
| Plasma Concentration of Giredestrant at Steady State by Dose Level | 58.8 ± 58.1 | 130 ± 59.1 | 441 ± 71.2 |
Collected over From Baseline to Day 43. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Giredestrant 10 mg | 0/17 (0%) | 1/17 (5.9%) | 12/17 (70.6%) |
| Giredestrant 30 mg | 0/40 (0%) | 2/40 (5%) | 21/40 (52.5%) |
| Giredestrant 100 mg | 0/17 (0%) | 1/17 (5.9%) | 14/17 (82.4%) |
| All Participants, Safety: Giredestrant (10, 30, or 100 mg) | 0/74 (0%) | 4/74 (5.4%) | 47/74 (63.5%) |
| Event | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| Breast abscessInfections and infestations | 1/17 | 0/40 | 0/17 | 1/74 |
| DizzinessNervous system disorders | 0/17 | 0/40 | 1/17 | 1/74 |
| MastitisInfections and infestations | 0/17 | 1/40 | 0/17 | 1/74 |
| Breast haematomaReproductive system and breast disorders | 0/17 | 1/40 | 0/17 | 1/74 |
| Event | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | All Participants, Safety: Giredestrant (10, 30, or 100 mg) |
|---|---|---|---|---|
| FatigueGeneral disorders | 2/17 | 1/40 | 5/17 | 8/74 |
| NauseaGastrointestinal disorders | 3/17 | 5/40 | 1/17 | 9/74 |
| Procedural painInjury, poisoning and procedural complications | 2/17 | 1/40 | 3/17 | 6/74 |
| PhotopsiaEye disorders | 0/17 | 0/40 | 2/17 | 2/74 |
| Vision blurredEye disorders | 0/17 | 0/40 | 2/17 | 2/74 |
| Skin infectionInfections and infestations | 2/17 | 0/40 | 0/17 | 2/74 |
| SeromaInjury, poisoning and procedural complications | 2/17 | 1/40 | 2/17 | 5/74 |
| Hot flushVascular disorders | 2/17 | 3/40 | 1/17 | 6/74 |
| DizzinessNervous system disorders | 1/17 | 4/40 | 1/17 | 6/74 |
| DyspepsiaGastrointestinal disorders | 0/17 | 3/40 | 0/17 | 3/74 |
This is the Intent-to-Treat (ITT) Population, which includes all participants enrolled in the study regardless of whether they received any study drug.
| Age, Continuous(Years) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Mean | 63.4 ± 8.9 | 64.1 ± 9.4 | 64.1 ± 7.7 | 63.9 ± 8.8 |
| Sex: Female, Male(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Female | 17 | 40 | 18 | 75 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 0 | 4 |
| Not Hispanic or Latino | 4 | 19 | 6 | 29 |
| Unknown or Not Reported | 13 | 17 | 12 | 42 |
| Race/Ethnicity, Customized(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 16 | 38 | 17 | 71 |
| Multiple | 1 | 0 | 0 | 1 |
| Unknown | 0 | 1 | 0 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| ECOG Performance Status of 0 | 17 | 36 | 17 | 70 |
| ECOG Performance Status of 1 | 0 | 4 | 0 | 4 |
| Initial Staging of Breast Cancer (Breast Cancer History)(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Stage I | 9 | 19 | 10 | 38 |
| Stage II | 8 | 21 | 7 | 36 |
| Stage III | 0 | 0 | 1 | 1 |
| Tumor Grade (Breast Cancer History)(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Grade 1 | 6 | 13 | 4 | 23 |
| Grade 2 | 9 | 23 | 12 | 44 |
| Grade 3 | 2 | 4 | 2 | 8 |
| Nodal Status (Breast Cancer History)(Participants) | Giredestrant 10 mg | Giredestrant 30 mg | Giredestrant 100 mg | Total |
|---|---|---|---|---|
| Negative | 14 | 37 | 17 | 68 |
| Positive | 2 | 3 | 1 | 6 |
| Missing | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jul 2019 to primary completion in May 2021, 21 months.
Results were first posted in Mar 2023, 1 year 9 months after primary completion.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 21 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Giredestrant